Skip to main content
. 2016 Nov 11;9:6977–6985. doi: 10.2147/OTT.S117161

Figure 2.

Figure 2

The pooled OR from eight studies with 505 NSCLC samples and 419 nontumor samples showing the association between p14ARF promoter methylation and NSCLC in cancer versus nontumor samples, I2=0%, OR =4.54, 95% CI: 2.47–8.32, P<0.001.

Abbreviations: CI, confidence interval; NSCLC, non-small-cell lung cancer; OR, odds ratio.